About us

Our name Enara Bio™ is derived from an Arabic word meaning illumination, enlightenment and bringing light into the darkness.

We are the leaders in exploring the hidden depths of cancer and T-cell biology to discover and characterize Dark Antigens™, a novel class of shared immunotherapy targets that arise from altered cellular processes in cancer cells. We believe that Dark Antigens have the core attributes that will enable cancer immunotherapies to improve treatment outcomes for broad patient populations.

Enara Bio is backed by prominent life science investors, including RA Capital, Pfizer Ventures, M Ventures, Samsara BioCapital and SV Health Investors. We collaborate with world-leading companies and academic institutions, such as Boehringer Ingelheim and the Francis Crick Institute, to help drive our differentiated science-led approach.

Enara Bio Our Story Poster

Leadership Team

Kevin Pojasek
President and Chief Executive Officer
David Watson
Chief Operating Officer
Sophie Papa
Chief Medical Officer and Head of Translational Science
Joseph Dukes
Chief Scientific Officer
Stacey Davis
Chief Business Officer and Chief Financial Officer

Board of Directors

Scientific Advisors & Founders

Investors

Kevin Pojasek

President and Chief Executive Officer

Kevin joined Enara Bio in 2018 bringing 15 years of leadership and strategic investment experience in the biotech and pharmaceutical sector. He is also a Venture Partner at SV Health Investors and was previously an Entrepreneur-in-Residence at Atlas Ventures.

Kevin was formerly Chief Strategy and Business Officer and a member of the executive leadership team at Immunocore. In this role, he was responsible for shaping the company’s corporate, R&D and growth strategies, as well as for overseeing business development. He was also co-head of the company’s Infectious Disease Unit and helped lead the Bill & Melinda Gates Foundation investment of up to $40 million. Prior to joining Immunocore, Kevin was President and CEO of Quartet Medicine, a company he co-founded in 2013 while at Atlas Ventures and held senior executive R&D and corporate development roles at several other venture-backed companies.

Kevin has a PhD from the Biological Engineering Department at Massachusetts Institute of Technology.